PPP1R1A

PPP1R1A is a cAMP/PKA-responsive inhibitor of protein phosphatase 1 (PP1) that, upon phosphorylation at Thr35 by PKA, binds and inhibits PP1 catalytic activity, thereby amplifying phosphorylation-dependent signaling in multiple tissues (PMID:29059150, PMID:37676724). In pancreatic β-cells, PPP1R1A is transcriptionally controlled by MafA and PDX1 and is required for GLP1R/PKA-mediated amplification of glucose-stimulated insulin secretion, maintenance of β-cell identity gene expression, mitochondrial coupling efficiency, and mTOR/AKT signaling; its loss broadly disrupts insulin biosynthesis and exocytosis machinery (PMID:33631146, PMID:38574885, PMID:41359828). In the kidney distal tubule, dietary potassium suppresses PPP1R1A expression and dephosphorylates Thr35, relieving PP1 inhibition to promote NCC dephosphorylation and lower blood pressure (PMID:37676724). In Ewing sarcoma, PPP1R1A drives G1/S cell cycle progression through PP1 inhibition–dependent downregulation of p21 and p27 and consequent Rb hyperphosphorylation, promoting tumorigenesis and metastasis (PMID:29059150, PMID:32477459).

1. 2013 Medium

   Establishing that PPP1R1A protein is highly abundant and cytoplasmic in pancreatic β-cells provided the first evidence that this PP1 inhibitor has a tissue-selective role in islet biology.

   Evidence LC-MS/MS proteomics of FACS-purified β-cells, Western blotting across tissues, IHC, and plasma PPP1R1A measurement after STZ-induced β-cell destruction in rats

   PMID:23557701

   Open questions at the time

   • No functional assay for PP1 inhibition in β-cells was performed
   • Release mechanism not linked to any signaling role
2. 2014 Medium

   Demonstrating that PPP1R1A knockdown impairs insulin secretion in β-cells established a functional requirement beyond expression, linking PP1 inhibition to secretory output.

   Evidence siRNA knockdown in INS-1 832/13 cells with insulin secretion assay

   PMID:25489054

   Open questions at the time

   • Mechanism by which PPP1R1A promotes secretion not defined
   • No rescue or in vivo confirmation
3. 2017 High

   Identifying that PKA phosphorylation of PPP1R1A at Thr35 is required for PP1 binding, inhibition, and downstream oncogenic activity in Ewing sarcoma resolved the activation mechanism and placed PPP1R1A in a defined PKA→PP1 signaling axis.

   Evidence siRNA/shRNA depletion, constitutively active PPP1R1A mutant rescue of PKA inhibitor effects, in vitro proliferation/migration, orthotopic xenograft mouse model, RNA-seq in Ewing sarcoma cells

   PMID:29059150

   Open questions at the time

   • Direct PP1 substrates mediating oncogenic phenotype not identified
   • Whether Thr35 is the sole activating phosphosite was not addressed
4. 2020 High

   Showing that PPP1R1A depletion upregulates p21 and p27 and reduces Rb phosphorylation clarified the cell cycle mechanism downstream of PP1 inhibition in Ewing sarcoma.

   Evidence Loss-of-function depletion, cell cycle analysis, Western blotting for p21/p27/phospho-Rb, IGF-1R inhibitor combination, xenograft tumor model

   PMID:32477459

   Open questions at the time

   • Whether PP1 directly dephosphorylates Rb or acts indirectly through CDK-inhibitor regulation is unresolved
   • Histone gene transcription link not mechanistically defined
5. 2021 High

   Demonstrating that MafA drives PPP1R1A expression and that PPP1R1A is required for GLP1R/PKA-mediated GSIS amplification, PKA-target phosphorylation, and mitochondrial coupling connected PPP1R1A to incretin signaling and β-cell identity.

   Evidence siRNA knockdown of PPP1R1A and MafA in INS-1 cells, GSIS assay, phospho-Western blotting, mitochondrial coupling measurement, mRNA analysis

   PMID:33631146

   Open questions at the time

   • Specific PP1 substrates mediating GSIS amplification not identified
   • No in vivo β-cell-specific knockout model
6. 2023 High

   Genetic and dietary experiments in mice established that PPP1R1A/I1 controls NCC phosphorylation and blood pressure in the kidney distal tubule by gating PP1A activity, revealing a physiological role in potassium-dependent salt reabsorption.

   Evidence Constitutively active SPAK knock-in mice, dietary potassium manipulation, Western blotting for phospho-NCC and phospho-I1, blood pressure measurements

   PMID:37676724

   Open questions at the time

   • Direct physical interaction between PP1A and NCC not demonstrated biochemically in this study
   • Kidney-specific PPP1R1A knockout not performed
7. 2024 Medium

   Identifying PDX1 as a second transcriptional regulator of PPP1R1A and showing that PPP1R1A overexpression in human islets augments insulin secretion and upregulates MAFA, PDX1, and GLUT1 established a positive feedback loop maintaining β-cell function.

   Evidence Pdx1 and Ppp1r1a siRNA in INS-1 cells, PPP1R1A overexpression in human islets, insulin secretion assay, Western blotting, RNA-seq, glucose uptake assay

   PMID:38574885

   Open questions at the time

   • Whether PPP1R1A acts on PP1 to stabilize these transcription factors or through a parallel mechanism is unknown
   • No ChIP confirmation of PDX1 binding at the PPP1R1A promoter reported
8. 2025 Medium

   Unbiased proteomics after PPP1R1A silencing revealed broad disruption of insulin biosynthesis and exocytosis machinery proteins and reduced phospho-AKT/mTOR signaling, expanding the downstream landscape of PPP1R1A-mediated PP1 inhibition in β-cells.

   Evidence siRNA knockdown in INS-1 cells, label-free DIA mass spectrometry, pathway enrichment analysis, Western blotting for phospho-AKT

   PMID:41359828

   Open questions at the time

   • Proteomic changes are correlative; direct PP1 substrate identification not performed
   • No validation in primary human β-cells or in vivo models

• The direct PP1 substrates through which PPP1R1A mediates its tissue-specific effects — GSIS amplification in β-cells, NCC regulation in kidney, and cell cycle control in Ewing sarcoma — remain unidentified, and no β-cell- or kidney-specific conditional knockout model has been reported.
• No substrate-trapping or phosphoproteomics to identify direct PP1 targets downstream of PPP1R1A
• No conditional tissue-specific knockout in vivo
• Structural basis of PPP1R1A–PP1 interaction beyond Thr35 phosphosite not resolved